GMAB News and Press, Genmab A/S From 01/06/23

Summary FDA and EU approved, the joint therapy Enhertu is set to become a blockbuster. The therapy targets HER-2 cancers and is already expanding indications beyond breast cancer. With this successful antibody-drug conjugate, the entire sub-industry is now seeing renewed momentum he...

Genmab ( GMAB ) ( GMXAY ) ( OTCPK:GNMSF ) submitted a new drug application (NDA) to Japan's Ministry of Health, Labor and Welfare (MHLW) for subcutaneous epcoritamab (DuoBody-CD3xCD20) to treat patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) who had ...

Genmab A/S (Nasdaq: GMAB): JNDA submission supported by results of Japanese and global phase 2 clinical trials evaluating epcoritamab in patients with mature B-cell non-Hodgkin’s lymphoma (NHL), including relapsed/refractory large B-cell lymphoma (LBCL) Genmab A/S ...

Citi has downgraded Genmab ( GMAB ) to neutral from buy citing foreign exchange rates and potential delays for two pipeline assets. The firm has a DKR3055 price target (~1% upside based on Tuesday's close on the Nasdaq Nordic). Analyst Peter Verdult said that a next phase go/no-go dec...

Epcoritamab featured in multiple data disclosures, including four oral presentations Results presented from the phase 1b/2 EPCORE™ NHL-2 trial of epcoritamab combined with standard salvage therapy in patients with transplant eligible relapsed/refractory (R/R) diffuse large B-cell l...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips If there’s a silver lining regarding the coronavirus pandemic, it’s that it demonstrated the importance of the top biotech stock picks for 2023. While medical innovations may seem frustratingly slow, the Covid-19 ...

Green Thumb Industries (OTC: GTBIF) , SunPower (NASDAQ: SPWR) and Genmab (NASDAQ: GMAB) are all up this month, and are trading for at least 35 times earnings. Instead of being overpriced, though, there are solid reasons investors see potential in these hot stocks. All th...

Epcoritamab BLA accepted for FDA Priority review; FDA action date is May 21, 2023 Epcoritamab could become the first subcutaneous bispecific antibody approved for the treatment of LBCL BLA submission supported by positive EPCORE™ NHL-1 trial results ...

The following slide deck was published by Genmab A/S in conjunction with their 2022 Q3 earnings call. For further details see: Genmab A/S 2022 Q3 - Results - Earnings Call Presentation

Deutsche Bank downgraded Genmab ( GMAB ) to hold from buy saying that it is does not expect upcoming data on candidates to be presented at two upcoming conferences to lead to upside. The firm has a price target of DKK 3100 (~3% upside based on Friday's close on the Copenhagen ...